| 0 (0%) | 08-06 00:02 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 110.69 | 1-year : | 129.28 |
| Resists | First : | 94.77 | Second : | 110.69 |
| Pivot price | 94.46 |
|||
| Supports | First : | 93.85 | Second : | 93.28 |
| MAs | MA(5) : | 94.41 |
MA(20) : | 94.32 |
| MA(100) : | 93.13 |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 36 |
D(3) : | 56.1 |
| RSI | RSI(14): 49.1 |
|||
| 52-week | High : | 94.77 | Low : | 88.7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ATTR ] has closed above bottom band by 17.6%. Bollinger Bands are 43.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 94.4 - 94.93 | 94.93 - 95.42 |
| Low: | 92.78 - 93.49 | 93.49 - 94.14 |
| Close: | 93.2 - 94.22 | 94.22 - 95.15 |
Tue, 04 Aug 2026
AstraZeneca’s ATTR-CM Failure Strengthens the Case for BridgeBio - Technology Org
Mon, 03 Aug 2026
5 companies advancing ATTR assets in the wake of Wainua’s fail - BioSpace
Thu, 30 Jul 2026
Alnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026 - Fierce Pharma
Tue, 28 Jul 2026
Tafamidis Generic Wins EU Backing for ATTR Cardiomyopathy - Medscape
Wed, 22 Jul 2026
Royalty pens $425M deal for slice of AstraZeneca ATTR drug sales - Fierce Biotech
Tue, 23 Jun 2026
ATTR-CM Incidence, Prevalence Rose Sharply in the US - The American Journal of Managed Care® (AJMC®)
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|